EN | SE Contact us

Management Team


Michael Oredsson

President and CEO

Degree in International Business Administration from Lund University. Born 1960. Lives in Beddingestrand, Sweden. Employed since 2013. He was CEO of Probi AB 2007-2013. Former CEO of Biosignal in Australia, 2002-2007, and Nutripharma in Norway, 1999-2001. Before that he was responsible for building up Pharmacia’s OTC product division in Australia. He also held senior marketing positions at Nestlé and Mars Inc in Sweden, Germany and France.

Shareholding: 913,035

Options: Employee options: 18,719


Stefan Eriksson

Chief Financial Officer

MBA, Lund University. Born 1963. Lives in Lund, Sweden. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. He was employed by the Swedish Tax Authority 1996-1997. Previously he worked as an auditor at PricewaterhouseCoopers 1990-1995.

Shareholding: 114,641

Options: Employee options: 3,750


Björn Frendéus

Chief Scientific Officer

Doctor of Immunology. Born 1973. Lives in Landskrona, Sweden. Employed since 2001. Graduated from the Swedish Foundation for Strategic Research funded Biomedicine programmes within the Infection & Vaccinology programme in 2001. Visiting Professor at University of Southampton.

Shareholding: 317,151 (own and affiliated holdings)

Options: Employee options: 6,000


Andres McAllister

Chief Medical Officer

Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá), and holds a PhD from the Pasteur Institut/Université Paris. Born 1956. Lives in Geneva, Switzerland. He has perfomed academic work at the Pasteur Institut and the University of California San Francisco on cancer immunotherapy. Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/Pierre Fabre.

Shareholding: -

Options: -


Kristoffer Rudenholm Hansson

Senior Vice President, Technical Operations

Master of Science in Chemical engineering. Born 1974. Lives in Malmö Sweden. Employed since 2016 and responsible for process development and production of antibodies for clinical studies. He has more than 15 years’ experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S, DAKO A/S and Symphogen A/S.

Shareholding: 491,628 (whereof 148,176 in Sw. kapitalförsäkring)

Options: Stock options: 50,000